Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Endometrial Cancer
Primary: Evaluate Patients With Progression Free Survival (PFS) — 26 months
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Phase 2 N=50 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Uterine Corpus Carcinoma · Stage III Uterine Corpus Cancer AJCC v7
Primary: Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)). — 68…
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=21 Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Participant Responses — 2; 8; 4; 6 participants
Phase 2 N=34 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 90 Days After Treatment Start — 23.3 percentage of participants
Phase 3 N=1,381 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Recurrent Uterine Corpus Carcinoma · Stage IIIA Uterine Corpus Cancer AJCC v7 · Stage IIIB Uterine Corpus Cancer AJCC v7
Primary: Number of Participants Alive at Time of Last Follow-up. — 376; 385; 271; 280 Participants
Phase 2 N=53 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 — 0; 0; 0; 3 Participants
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 2 N=56 Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 31; 21 participants
Phase 2 N=70 BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Advanced Endometrial Cancer
Primary: Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status — 49; 21; 70; 1 number of participants
Phase 2 N=30 A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
Uterine Cancer
Primary: 3-year Overall Survival — 17 partipants
Phase 2 N=27 A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Neoplasms · Neoplasms by Site · Urogenital Neoplasms
Primary: Tumor Response — 0; 1; 12; 11 participants
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Phase 2 N=41 Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Percent of Patients Estimated to be Progression-Free and Alive — 86; 76; 68 Percentage of Patients
Phase 2 N=16 ZW25 in Women With Endometrial Cancers
Endometrial Cancer · Carcinosarcoma
Primary: Overall Response Rate/ORR of Participants — 1; 15 Participants
Phase 2 N=33 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Overall Disease Control Rate — 17 percentage of participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=32 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients Completing the Protocol — 27 Participants
Phase 2 N=28 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Response — 0 percentage of participants
Phase 2 N=133 Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Endometrial Cancer
Primary: Objective Response Rate (ORR) — 14.3 Percentage of participants
Phase 2 N=35 RAD001 in Recurrent Endometrial Cancer Patients
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants
Phase 2 N=11 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Endometrioid Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Frequency of Objective Response Defined by RECIST 1.1 Criteria — 0.0 percentage of participants
Phase 2 N=54 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants
Phase 2 N=37 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mucinous Adenocarcinoma
Primary: Number of Participants With Adverse Events — 1; 1; 2; 4 Participants
Phase 2 N=15 Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
Endometrial Carcinoma
Primary: Number of Participants With Progression Free Survival (PFS=Date of Progression of Disease or Death) at 6 Months Using Bevacizumab, Carboplatin, and Paclitaxel in…
Phase 2 N=49 VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: 6 Month Progression-free Survival — 18 participants
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…